Claims
- 1. An isolated protein capable of affecting an absicisic acid (ABA) response and comprising:(i) a hydrophobic C-terminus; (ii) at least one coiled coil region; (iii) an EF-hand consensus sequence; (iv) a nucleotide binding site; and optionally (v) a hydrophilic N-terminus; wherein said protein participates in ABA signalling as measured by its ability to participate in ABA-mediated control of ion channels.
- 2. An isolated protein according to claim 1 which is capable of being cleaved by the toxin botulinum C.
- 3. An isolated protein according to claim 1 wherein the hydrophobic C-terminus comprises the sequence from position 282 to position 296 of the amino acid sequence shown in SEQ ID NO:2.
- 4. An isolated protein according to claim 1 wherein the hydrophobic C-terminus comprises the sequence from position 280 to position 294 of the amino acid sequence shown in SEQ ID NO:2.
- 5. An isolated protein according to claim 1 wherein there are three coiled coil regions.
- 6. An isolated protein according to claim 1 wherein said at least one coiled coil region comprises the sequence from position 210 to position 247 of the amino acid sequence shown in SEQ ID NO:2.
- 7. An isolated protein according to claim 1 wherein said at least one coiled coil regions comprises the sequence from position 216 to position 240 of the amino acid sequence shown in SEQ ID NO:2.
- 8. An isolated protein according to claim 1 wherein said at least one coiled coil region corresponds to an epimorphin pattern.
- 9. An isolated protein according to claim 6 wherein said at least one coiled coil region corresponds to an epimorphin pattern.
- 10. An isolated protein according to claim 1 wherein said hydrophilic N-terminus comprises the sequence from position 1 to position 280 of the amino acid sequence shown in SEQ ID NO:2.
- 11. An isolated protein according to claim 1 wherein the hydrophilic N-terminus comprises the sequence from position 1 to position 279 of the amino acid sequence shown in SEQ ID NO:2.
- 12. An isolated protein according to claim 1 wherein said nucleotide binding site comprises the sequence of positions 114 to 119 of the amino acid sequence shown in SEQ ID NO:2.
- 13. An isolated protein according to claim 1 wherein the nucleotide binding site comprises the sequence of positions 116, 118 and 120 of the amino acid sequence shown in SEQ ID NO:2.
- 14. An isolated protein according to claim 1 wherein said EF-hand consensus sequence comprises the sequence from position 16 to 28 of the amino acid sequence shown in SEQ ID NO:2.
- 15. An isolated protein according to claim 1 wherein said hydrophobic C-terminus comprises a membrane spanning region.
- 16. An isolated protein according to claim 1 that is derived from a plant.
- 17. An isolated protein according to claim 1, wherein said protein affects ABA-mediated control of guard cell K+ and Cl− channels.
- 18. An isolated protein according to claim 1, wherein said protein affects ABA-mediated stoma closure regulation in a plant.
- 19. The isolated protein according to claim 1, wherein the protein, when overexpressed in a host cell, augments ABA signalling as measured by its ability to participate in ABA-mediated control of ion channels.
- 20. An isolated protein comprising the amino acid sequence shown in SEQ ID NO:2, or a biologically active fragment thereof, wherein said protein, or said biologically active fragment thereof participates in absicisic acid (ABA) signalling as measured by its ability to participate in ABA-mediated control of ion channels.
- 21. An isolated protein comprising amino acids 1-279 of SEQ ID NO:2, or a biologically active fragment thereof, wherein said protein or said biologically active fragment thereof inhibits an absicisic acid (ABA) response.
- 22. The isolated protein according to claim 21, wherein the protein or biologically active fragment thereof inhibits an ABA response as measured by the ability to inhibit ABA-mediated control of ion channels.
- 23. The isolated protein according to claim 21, wherein the protein comprises amino acids 1-279 of SEQ ID NO:2.
- 24. An isolated protein which affects an absicisic acid (ABA) response and comprises an amino acid sequence having at least 50% identity to the amino acid sequence shown in SEQ ID NO:2, wherein said protein participates in ABA signalling as measured by its ability to participate in ABA-mediated control of ion channels.
- 25. An isolated protein which affects an absicisic acid (ABA) response and comprises an amino acid sequence having at least 75% identity to the amino acid sequence shown in SEQ ID NO:2, wherein said protein participates in ABA signalling as measured by its ability to participate in ABA-mediated control of ion channels.
- 26. An isolated protein which affects an absicisic acid (ABA) response and comprises an amino acid sequence having at least 85% identity to the amino acid sequence shown in SEQ ID NO:2, wherein said protein participates in ABA signalling as measured by its ability to participate in ABA-mediated control of ion channels.
- 27. An isolated protein which affects an absicisic acid (ABA) response and comprises an amino acid sequence having at least 95% identity to the amino acid sequence shown in SEQ ID NO:2, wherein said protein participates in ABA signalling as measured by its ability to participate in ABA-mediated control of ion channels.
- 28. An isolated protein which comprises the amino acid sequence shown in SEQ ID NO:2, wherein said protein or fragment thereof participates in ABA signalling as measured by its ability to participate in ABA-mediated control of ion channels.
- 29. An isolated protein according to any one of claims 24-27, wherein said protein is capable of being cleaved by the toxin botulinum C.
- 30. A method of screening for protein-protein interaction comprising:a) contacting a protein according to any one of claims 1-20 with an expressed candidate absicisic acid (ABA) signalling component; and b) detecting interaction between said protein and said ABA signalling component.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9720784 |
Sep 1997 |
GB |
|
Parent Case Info
This application claims the benefit of priority under 35 U.S.C. § 371 to PCT Patent Application No. PCT/GB98/02937, filed Sep. 30, 1998, which designated the United States and was published in English, and which claims the benefit of foreign priority under 35 U.S.C. § 119 to Great Britain Patent Application No. 9720784.9, filed Sep. 30, 19971.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/GB98/02937 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO99/16880 |
4/8/1999 |
WO |
A |
Non-Patent Literature Citations (2)
Entry |
Leung et al. 1994; Science 264:1448-1452.* |
Silhavy et al. 1995; Plant Molecular Biology 27:587-595. |